The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials

Fan, Simin; Shi, Xiaoyan; Yao, Jia; Zhong, Min; Feng, Peimin

doi:10.17235/reed.2020.6392/2019

Cited by 8 publications

(8 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In line with our results, a previous meta‐analysis revealed that GLP‐1 RA therapy significantly increases adiponectin (WMD 0.66 μg/mL, 95% CI 0.37–0.95, P < .001) 37 . However, this finding was obtained in a subgroup analysis of secondary outcomes that only included 3 randomized controlled trials in patients with nonalcoholic fatty liver disease.…”

Section: Discussionsupporting

confidence: 91%

“…In line with our results, a previous meta-analysis revealed that GLP-1 RA therapy significantly increases adiponectin (WMD 0.66 μg/mL, 95% CI 0.37-0.95, P < .001). 37 However, this finding was obtained in a subgroup analysis of secondary outcomes that only included 3 randomized controlled trials in patients with nonalcoholic fatty liver disease. Furthermore, our meta-analysis demonstrated a greater impact of GLP-1 RA on adiponectin levels than a low-calorie diet (0.34 μg/mL, 95% CI 0.17-0.50), 38 exercise (WMD 0.44 μg/mL; 95% CI 0.13-0.75), 39 metformin treatment (WMD 0.19 μg/mL; 95% CI 0.09-0.30), 40 and sodium-glucose cotransporter 2 inhibitor treatment (WMD 0.30 μg/mL; 95% CI 0.22-0.38), 41 and a similar effect to dipeptidyl peptidase-4 inhibitors (WMD 0.74 μg/mL; 95% CI 0.45-1.03).…”

Section: F I G U R E 1 Flow Chart Of the Number Of Studies Included For Meta-analysismentioning

confidence: 99%

See 1 more Smart Citation

Impact of glucagon‐like peptide‐1 receptor agonists on adiponectin concentrations: A meta‐analysis of randomized controlled trials

Simental‐Mendía

Sánchez‐García

Linden-Torres

et al. 2021

Brit J Clinical Pharma

View full text Add to dashboard Cite

Previous studies have reported an elevation in adiponectin concentrations using glucagon-like peptide-1 receptor agonists (GLP-1 RA) therapy; however, this possible pleiotropic effect is still uncertain. Thus, the objective of this meta-analysis of randomized controlled trials was to assess the impact of GLP-1 RA on adiponectin levels.Methods: This systematic review and meta-analysis included randomized controlled trials investigating the effect of GLP-1 RA on circulating adiponectin concentrations.Studies from PubMed, Web of Science, Scopus, and Google Scholar databases were included. A random-effects model and a sensitivity analysis using the leave 1-out method were conducted.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: F I G U R E 1 Flow Chart Of the Number Of Studies Included For Meta-analysismentioning

confidence: 99%

Impact of glucagon‐like peptide‐1 receptor agonists on adiponectin concentrations: A meta‐analysis of randomized controlled trials

Simental‐Mendía

Sánchez‐García

Linden-Torres

et al. 2021

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…In the past decade, there have been some meta-analyses for GLP-RA treatment of MAFLD ( 33 , 34 ). Dong et al ( 33 ) evaluated three RCTs and three observational studies (a total of 329 people), among which one RCT and two observational trials used liver pathological biopsy as a diagnostic method.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis

Dai

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

AimsMetabolic associated fatty liver disease (MAFLD) is the most common cause of chronic liver disease and is a major health and economic burden in society. New drugs are urgently needed to treat MAFLD. This systematic review and meta-analysis was conducted to evaluate the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with MAFLD.MethodWe searched PubMed, Embase, Cochrane Library database, and Web of Science since 1977. We selected all randomized controlled trials which met the inclusion and exclusion criteria and evaluated the quality of evidence. A random-effects meta-analysis was performed to assess all the primary and second outcomes.ResultsEight randomized controlled trials, including 396 patients, of which 265 patients had type 2 diabetes mellitus, met the inclusion criteria. Compared with the placebo or active agents group, the GLP-RA group showed a significant reduction in the liver fat content [weight mean difference (WMD) -3.17%, 95%CI -5.30 to -1.03, P < 0.0001], body weight (WMD -4.58 kg, 95%CI -8.07 to -1.10, P = 0.010), waist circumference (WMD -3.74 cm, 95%CI -6.73 to -0.74, P = 0.010), alanine aminotransferase (WMD -10.73 U/L, 95%CI -20.94 to -0.52, P = 0.04), γ- glutamyl transferase (WMD -12.25 U/L,95% -18.85 to -5.66, P = 0.0003, with I²=23%), fasting blood glucose (MD, -0.36 mmol/L; 95%CI, -0.69 to -0.03, P = 0.030), and hemoglobin A1c (WMD -0.36%, 95%CI -0.52 to -0.19, P < 0.0001). The reported adverse events were gastrointestinal complications with no serious adverse events, and most symptoms were relieved within 1–2 weeks after dose titration.ConclusionGLP-RAs may improve liver injury and metabolic disorder in patients with MAFLD, regardless of the presence of type 2 diabetes mellitus. The benefits of GLP-RAs treatment outweigh the adverse effects of drugs in patients with MAFLD.

show abstract

“…They observed that pioglitazone decreases liver steatosis but that they have no effect on liver fibrosis and inflammation. It has been observed that treatment with a GLP-1 receptor antagonist improves body mass index, adiponectin, and liver fat fraction in NAFLD patients [ 74 ]. The second group of drugs targets inflammation and oxidative stress.…”

Section: Diagnosis and Management Of Nafld In Pcos And Future Investigationsmentioning

confidence: 99%

Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS)

et al. 2022

View full text Add to dashboard Cite

Background: Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders in women’s reproductive period of life. The presence of nonalcoholic fatty liver disease NAFLD, one of the leading causes of chronic liver disease in the Western world, is increased in women with PCOS. This review aims to present current knowledge in epidemiology, pathophysiology, diagnostics, and treatment of NAFLD in PCOS with an emphasis on the molecular basis of development of NAFLD in PCOS women. Methods: Authors investigated the available data on PCOS and NAFLD by a MEDLINE and Pub Med search during the years 1990–2021 using a combination of keywords such as “PCOS”, “NAFLD”, “steatohepatitis”, “insulin resistance”, “hyperandrogenaemia”, “inflammation”, “adipose tissue”, and “obesity”. Peer-reviewed articles regarding NAFLD and PCOS were included in this manuscript. Additional articles were identified from the references of relevant papers. Results: PCOS and NAFLD are multifactorial diseases, The development of NAFLD in PCOS women is linked to insulin resistance, hyperandrogenemia, obesity, adipose tissue dysfunction, and inflammation. There is the possible role of the gut microbiome, mitochondrial dysfunction, and endocannabinoid system in the maintenance of NAFLD in PCOS women. Conclusions: There is a need for further investigation about the mechanism of the development of NAFLD in PCOS women. New data about the molecular basis of development of NAFLD in PCOS integrated with epidemiological and clinical information could influence the evolution of new diagnostic and therapeutic approaches of NAFLD in PCOS.

show abstract

The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials

Cited by 8 publications

References 35 publications

Impact of glucagon‐like peptide‐1 receptor agonists on adiponectin concentrations: A meta‐analysis of randomized controlled trials

Impact of glucagon‐like peptide‐1 receptor agonists on adiponectin concentrations: A meta‐analysis of randomized controlled trials

Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis

Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS)

Contact Info

Product

Resources

About